Tania Papkovskaia qualified with a B.Sc. in Biochemistry from University College Dublin in 2009 and earned a PhD in Clinical Neuroscience from University College London, sponsored by Eisai Limited in collaboration with the Welcome Trust Consortium and the Institute of Neurology. In addition, she conducted postdoctoral research at the department of Oncology, University of Cambridge, investigating the role of cyclin-dependent kinase inhibitors in neuroblastoma.
In 2014, Tania joined the Healthcare team at the Gerson Lehrman Group, providing diligence support to global healthcare investors, coordinating business development efforts and product campaigns across pharmaceutical, biotechnology and medical device segments. In 2017, she took over the European Healthcare team, a $4.5 million division, with responsibility spanning revenue, commercial strategy, operational performance, training and development.